0
0

Slaying the Cyclops

How the Twelve-Eyed Toad Sees What One Eye Cannot

A working treatise by Bevin Brooks

The Cyclops had one eye. One eye sees flat… no depth, no distance, no second opinion. And that’s every one of us if we’re honest. Every founder, every farmer alone with the thing they know, looking from the one spot they happen to stand on, falling in love with what they see and calling it truth. The oldest mistake isn’t being dumb. It’s being singular.

The fix isn’t getting smarter. A smarter Cyclops still has one eye. The fix is more eyes… set around the same thing, each catching what the others can’t. That’s the Twelve-Eyed Toad.

This is the oldest fight in philosophy, the One versus the Many. A hundred years ago William James planted his flag with the Many. He said the world isn’t a uni-verse, it’s a multi-verse… many real centers bumping into each other, the unity always partial, never sealed. He called the monist’s tidy world the block-universe. That’s the Cyclops exactly. One view, declared whole.

The Cyclops has a name out here in the dirt, and the name is consolidation. Big Ag is the one-eyed giant… one crop fence to fence, one buyer at the gate. Monoculture is just monism with a tractor on it. Take this price or take nothing. The farmer who grew the thing ends up the lowest-paid link in somebody else’s chain, picked off one at a time because every farmer’s standing there alone.

The answer isn’t one bigger farmer. A bigger Cyclops is still a Cyclops. The answer is a bunch of small farms that see together… growers and processors set around the same crop, each bringing the eye the others don’t have. That’s an AgriCluster. The Toad made out of real farms. It flips vertical integration on its head… integration by the farmers, not the giant. The money runs the other way. Down. Into the field, into the little town.

This is why the little emerging crops matter, and why the clock’s running. Elderberry, pawpaw, aronia, hazelnut… the ones the giant hasn’t flattened yet… still many growers, many ways, no single buyer owning the gate. The whole fight is to shape these crops on our terms before consolidation rolls in.

One thing keeps it honest. The Toad makes the questions… but reality casts the deciding vote. A bench of brilliant people can still be confidently wrong together. The eyes tell you what to go check. The numbers and the market tell you the answer.

So here’s the whole of it, and it’s a fight, not a meditation. Refuse the single view. Refuse the single buyer. Refuse the block-market. Build the bench. Build the cluster. Keep the crop plural, keep it farmer-held, keep the value down in the field that grew it.

The Cyclops is big. But it’s got one eye. We’ve got many. That’s how the small farm wins.

Facebook
X
LinkedIn

More in Spotlight:

Load More

METABOLIC RECOVERY – The Next Phase of the GLP-1 Conversation: Metabolic Recovery

Lionberry 's Weekly Delusion and Re-illusion Update.

For the last two years, we’ve been talking about GLP-1 drugs.

Ozempic. Wegovy. Zepbound.

They work.

They reduce appetite, improve blood sugar regulation, and are reshaping metabolic health at scale. This is one of the most significant shifts we’ve seen in decades (Wilding et al., 2021).

But a quieter question is starting to emerge:

What happens after?

Because many people eventually discontinue these medications. They’re expensive, often require ongoing use, and studies have shown substantial weight regain can occur after discontinuation of GLP-1 therapies (Wilding et al., 2022).

Not because people failed.

Because the system that was being supported… is no longer being supported.

I believe we’re entering a new phase of this conversation.

Not just weight loss.

Not just appetite suppression.

But metabolic recovery.

What does the body need to help maintain stability after intervention?

The Washington State University elderberry study led by Professor Patrick Solverson and colleagues, published in 2024, caught my attention immediately (Solverson et al., 2024). Last summer, I also had the opportunity to hear the research presented during the International Elderberry Symposium.

As both an elderberry farmer and a value-added product maker, I was excited to see rigorous science emerging around American elderberry — but also genuinely curious why it wasn’t making larger headlines.

Because the findings were interesting.

In the randomized controlled trial, participants consuming 100% American elderberry juice for one week demonstrated:

  • Reduced blood glucose
  • Lower insulin levels
  • Increased fat oxidation
  • Measurable shifts in gut microbiome activity (Solverson et al., 2024)

Not a miracle.

Not hype.

But a signal.

Because the mechanism matters.

One detail that makes American elderberry especially interesting is that its anthocyanin profile appears to differ from many other dark berries.

American elderberry (Sambucus canadensis) contains significant amounts of acylated anthocyanins — particularly acylated cyanidin-based compounds connected to hydroxycinnamic acid groups (Lee & Finn, 2007; Özgen et al., 2010). These acyl groups alter the chemistry and stability of the anthocyanin molecule.

Why does that matter?

Research suggests acylated anthocyanins demonstrate greater resistance to heat, oxidation, light degradation, and digestive breakdown compared to many non-acylated anthocyanins commonly found in fruits such as blackberries and in many European elderberry varieties (Sadilova et al., 2006; Fuleki & Francis, 1968).

That stability may matter biologically because it potentially allows more intact anthocyanin compounds to survive processing, storage, digestion, and interaction with the gut microbiome.

European elderberry (Sambucus nigra) contains a different anthocyanin composition, dominated more heavily by non-acylated cyanidin 3-glucoside and cyanidin 3-sambubioside compounds (Lee & Finn, 2007). Other berries absolutely contain beneficial anthocyanins too — but American elderberry appears to possess a somewhat distinct anthocyanin architecture that researchers are still working to fully understand.

Researchers believe these anthocyanins interact with the gut microbiome, helping generate short-chain fatty acids and downstream metabolites associated with insulin sensitivity, inflammation regulation, and endogenous GLP-1 signaling pathways (Chambers et al., 2018; Solverson et al., 2024).

Not synthetically.

Endogenously.

Through food and the gut microbiome.

To me, this is where the conversation may be heading next.

Not:

“What replaces GLP-1 drugs?”

But:

“What helps support the body alongside them — and after them?”

Or even:

“What supports metabolic health for people who never start them at all?”

For too long, metabolism has been framed as something we “fix.”

I think we’re moving toward something different:

Metabolism as something we support daily — through food, hydration, gut health, and the biological systems we nourish over time.

For the past year, I’ve been quietly studying this space and building around one core idea:

There may be a meaningful role for real functional food in the GLP-1 era — not as a replacement for medicine, but as nutritional support alongside metabolic health journeys.

Not a shortcut.

A system.

We’re still early in this conversation.

But if the last few years were about intervention…

the next few may be about recovery.

Curious what others in food, agriculture, metabolic health, and functional wellness are seeing emerge in this space.

— Bevin Brooks

References

Solverson, P., Teets, C., Rust, B., Johnson, S.A., et al. (2024). A One-Week Elderberry Juice Intervention Augments the Fecal Microbiota and Suggests Improvement in Glucose Tolerance and Fat Oxidation in a Randomized Controlled Trial. Nutrients, 16(20), 3555.

Wilding, J.P.H., Batterham, R.L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002.

Wilding, J.P.H., Jacobsen, L.V., le Roux, C.W., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.

Lee, J., & Finn, C.E. (2007). Anthocyanins and Other Polyphenolics in American Elderberry (Sambucus canadensis) and European Elderberry (Sambucus nigra) Cultivars. Journal of the Science of Food and Agriculture, 87(14), 2665–2675.

Özgen, M., Scheerens, J.C., Reese, R.N., & Miller, R.A. (2010). Total Phenolic, Anthocyanin Contents and Antioxidant Capacity of Selected Elderberry Accessions. Pharmacognosy Magazine, 6(23), 198–203.

Sadilova, E., Stintzing, F.C., & Carle, R. (2006). Thermal degradation of acylated and nonacylated anthocyanins. Journal of Food Science, 71(8), C504–C512.

Fuleki, T., & Francis, F.J. (1968). Quantitative Methods for Anthocyanins: Stability of Elderberry Pigments. Journal of Food Science, 33(1), 72–79.

Chambers, E.S., Preston, T., Frost, G., & Morrison, D.J. (2018). Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health. Current Nutrition Reports, 7, 198–206.